nach oben

Cancer and Metastasis Reviews

Erschienen in:

16.09.2019 | Metastasis

Functional disparities within the TIMP family in cancer: hints from molecular divergence

verfasst von: Celina Eckfeld, Daniel Häußler, Benjamin Schoeps, Chris D. Hermann, Achim Krüger

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The members of the tissue inhibitor of metalloproteinase (TIMP) family (TIMP-1, 2, 3, 4) are prominently appreciated as natural inhibitors of cancer-promoting metalloproteinases. However, clinical and recent functional studies indicate that some of them correlate with bad prognosis and contribute to the progression of cancer and metastasis, pointing towards mechanisms beyond inhibition of cancer-promoting proteases. Indeed, it is increasingly recognized that TIMPs are multi-functional proteins mediating a variety of cellular effects including direct cell signaling. Our aim was to provide comprehensive information towards a better appreciation and understanding of the biological heterogeneity and complexity of the TIMPs in cancer. Comparison of all four members revealed distinct cancer-associated expression patterns and distinct prognostic impact including a clear correlation of TIMP-1 with bad prognosis for almost all cancer types. For the first time, we present the interactomes of all TIMPs regarding overlapping and non-overlapping interaction partners. Interestingly, the overlap was maximal for metalloproteinases (e.g., matrix metalloproteinase 1, 2, 3, 9) and decreased for non-protease molecules, especially cell surface receptors (e.g., CD63, overlapping only for TIMP-1 and 4; IGF-1R unique for TIMP-2; VEGFR2 unique for TIMP-3). Finally, we attempted to identify and summarize experimental evidence for common and unique structural traits of the four TIMPs on the basis of amino acid sequence and protein folding, which account for functional disparities. Altogether, the four TIMPs have to be appreciated as molecules with commonalities, but, more importantly, functional disparities, which need to be investigated further in the future, since those determine their distinct roles in cancer and metastasis.

Nur mit Berechtigung zugänglich

Lambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004). TIMPs as multifacial proteins. Critical Reviews in Oncology/Hematology, 49(3), 187–198.PubMedCrossRef

Lu, P., Takai, K., Weaver, V. M., & Werb, Z. (2011). Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harbor Perspectives in Biology, 3, a005058.

Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biology: Journal of the International Society for Matrix Biology, 44-46, 247–254.CrossRef

Bonnans, C., Chou, J., & Werb, Z. (2014). Remodelling the extracellular matrix in development and disease. Nature Reviews Molecular Cell Biology, 15(12), 786–801.PubMedPubMedCentralCrossRef

Brand, K. (2002). Cancer gene therapy with tissue inhibitors of metalloproteinases (TIMPs). Current Gene Therapy, 2(2), 255–271.PubMedCrossRef

Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284(5751), 67–68.PubMedCrossRef

Köppel, P., Baici, A., Keist, R., Matzku, S., & Keller, R. (1984). Cathepsin B-like proteinase as a marker for metastatic tumor cell variants. Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology, 52(5), 293–299.CrossRef

Thorgeirsson, U. P., Liotta, L., Kalebic, T., Thomas, K., Rios-Candelore, M., & Russo, R. G. (1982). Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro. Journal of the National Cancer Institute, 69(5), 1049–1054.PubMed

Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F.-Y., Greenbaum, D. C., Hager, J. H., Bogyo, M., & Hanahan, D. (2004). Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell, 5(5), 443–453.PubMedCrossRef

10.

Albini, A., Melchiori, A., Santi, L., Liotta, L. A., Brown, P. D., & Stetler-Stevenson, W. G. (1991). Tumor cell invasion inhibited by TIMP-2. Journal of the National Cancer Institute, 83(11), 775–779.PubMedCrossRef

11.

Khokha, R. (1994). Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. Journal of the National Cancer Institute, 86(4), 299–304.PubMedCrossRef

12.

Rigg, A. S., & Lemoine, N. R. (2001). Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Therapy, 8(11), 869–878.PubMedCrossRef

13.

Jiang, Y., Goldberg, I. D., & Shi, Y. E. (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene, 21(14), 2245–2252.PubMedCrossRef

14.

Baker, A. H., George, S. J., Zaltsman, A. B., Murphy, G., & Newby, A. C. (1999). Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. British Journal of Cancer, 79(9), 1347–1355.PubMedPubMedCentralCrossRef

15.

McCarthy, K., Maguire, T., McGreal, G., McDermott, E., O’Higgins, N., & Duffy, M. J. (1999). High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. International Journal of Cancer, 84(1), 44–48.PubMedCrossRef

16.

Remacle, A., McCarthy, K., Noël, A., Maguire, T., McDermott, E., O’Higgins, N., Foidart, J. M., & Duffy, M. J. (2000). High levels of TIMP-2 correlate with adverse prognosis in breast cancer. International Journal of Cancer, 89(2), 118–121.PubMedCrossRef

17.

Kopitz, C., Gerg, M., Bandapalli, O. R., Ister, D., Pennington, C. J., Hauser, S., Flechsig, C., Krell, H.-W., Antolovic, D., Brew, K., Nagase, H., Stangl, M., von Weyhern, C. W. H., Brücher, B. L. D. M., Brand, K., Coussens, L. M., Edwards, D. R., & Krüger, A. (2007). Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Research, 67(18), 8615–8623.PubMedCrossRef

18.

Schelter, F., Grandl, M., Seubert, B., Schaten, S., Hauser, S., Gerg, M., Boccaccio, C., Comoglio, P., & Krüger, A. (2011). Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clinical & Experimental Metastasis, 28(8), 793–802.CrossRef

19.

Seubert, B., Grünwald, B., Kobuch, J., Cui, H., Schelter, F., Schaten, S., Siveke, J. T., Lim, N. H., Nagase, H., Simonavicius, N., Heikenwalder, M., Reinheckel, T., Sleeman, J. P., Janssen, K. P., Knolle, P. A., & Krüger, A. (2015). Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology, 61(1), 238–248.PubMedCrossRef

20.

Cui, H., Seubert, B., Stahl, E., Dietz, H., Reuning, U., Moreno-Leon, L., Ilie, M., Hofman, P., Nagase, H., Mari, B., & Krüger, A. (2015). Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene, 34(28), 3640–3650.PubMedCrossRef

21.

Grünwald, B., Schoeps, B., & Krüger, A. (2019). Recognizing the molecular multifunctionality and interactome of TIMP-1. Trends in Cell Biology, 29(1), 6–19.PubMedCrossRef

22.

Ries, C. (2014). Cytokine functions of TIMP-1. Cellular and Molecular Life Sciences, 71(4), 659–672.PubMedCrossRef

23.

Chirco, R., Liu, X.-W., Jung, K.-K., & Kim, H.-R. C. (2006). Novel functions of TIMPs in cell signaling. Cancer Metastasis Reviews, 25(1), 99–113.PubMedCrossRef

24.

Mason, S. D., & Joyce, J. A. (2011). Proteolytic networks in cancer. Trends in Cell Biology, 21(4), 228–237.PubMedCrossRef

25.

Murthy, A., Cruz-Munoz, W., & Khokha, R. (2008). TIMPs: Extracellular modifiers in cancer development. In D. Edwards, G. Hoyer-Hansen, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome (pp. 373–400). Springer.

26.

Murphy, G., Cawston, T. E., & Reynolds, J. J. (1981). An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases. The Biochemical Journal, 195(1), 167–170.PubMedPubMedCentralCrossRef

27.

Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T. J. R., Murphy, G., & Reynolds, J. J. (1985). Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature, 318(6041), 66–69.PubMedCrossRef

28.

Gasson, J. C., Golde, D. W., Kaufman, S. E., Westbrook, C. A., Hewick, R. M., Kaufman, R. J., Wong, G. G., Temple, P. A., Leary, A. C., Brown, E. L., Orr, E. C., & Clark, S. C. (1985). Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature, 315(6022), 768–771.PubMedCrossRef

29.

Cruz-Munoz, W., & Khokha, R. (2008). The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Critical Reviews in Clinical Laboratory Sciences, 45(3), 291–338.PubMedCrossRef

30.

Goldberg, G. I., Marmer, B. L., Grant, G. A., Eisen, A. Z., Wilhelm, S., & He, C. S. (1989). Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proceedings of the National Academy of Sciences of the United States of America, 86(21), 8207–8211.PubMedPubMedCentralCrossRef

31.

Hamze, A. B., Wei, S., Bahudhanapati, H., Kota, S., Acharya, K. R., & Brew, K. (2007). Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors. Protein Science, 16(9), 1905–1913.PubMedPubMedCentralCrossRef

32.

Stetler-Stevenson, W. G., Bersch, N., & Golde, D. W. (1992). Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Letters, 296(2), 231–234.PubMedCrossRef

33.

Stetler-Stevenson, W. G., Brown, P. D., Onisto, M., Levy, A. T., & Liotta, L. A. (1990). Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. The Journal of Biological Chemistry, 265(23), 13933–13938.PubMed

34.

Pavloff, N., Staskus, P. W., Kishnani, N. S., & Hawkes, S. P. (1992). A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. The Journal of Biological Chemistry, 267(24), 17321–17326.PubMed

35.

Greene, J., Wang, M., Liu, Y. E., Raymond, L. A., Rosen, C., & Shi, Y. E. (1996). Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. The Journal of Biological Chemistry, 271(48), 30375–30380.PubMedCrossRef

36.

Terpos, E., Dimopoulos, M. A., Shrivastava, V., Leitzel, K., Christoulas, D., Migkou, M., Gavriatopoulou, M., Anargyrou, K., Hamer, P., Kastritis, E., Carney, W., & Lipton, A. (2010). High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 34(3), 399–402.PubMedCrossRef

37.

Fong, K. M., Kida, Y., Zimmerman, P. V., & Smith, P. J. (1996). TIMP1 and adverse prognosis in non-small cell lung cancer. Clinical Cancer Research, 2(8), 1369–1372.PubMed

38.

Honkavuori, M., Talvensaari-Mattila, A., Puistola, U., Turpeenniemi-Hujanen, T., & Santala, M. (2008). High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Research, 28(5A), 2715–2719.PubMed

39.

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., & Asplund, A. (2015). Tissue-based map of the human proteome. Science, 347(6220), 1260419.PubMedCrossRef

40.

Lichtinghagen, R., Musholt, P. B., Lein, M., Römer, A., Rudolph, B., Kristiansen, G., Hauptmann, S., Schnorr, D., Loening, S. A., & Jung, K. (2002). Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. European Urology, 42(4), 398–406.PubMedCrossRef

41.

Grünwald, B., Harant, V., Schaten, S., Frühschütz, M., Spallek, R., Höchst, B., Stutzer, K., Berchtold, S., Erkan, M., Prokopchuk, O., Martignoni, M., Esposito, I., Heikenwalder, M., Gupta, A., Siveke, J., Saftig, P., Knolle, P., Wohlleber, D., & Krüger, A. (2016). Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver. Gastroenterology, 151(5), 1011–1024.PubMedCrossRef

42.

Prokopchuk, O., Grünwald, B., Nitsche, U., Jäger, C., Prokopchuk, O. L., Schubert, E. C., Friess, H., Martignoni, M. E., & Krüger, A. (2018). Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer. BMC Cancer, 18(1), 128.PubMedPubMedCentralCrossRef

43.

Laitinen, A., Hagström, J., Mustonen, H., Kokkola, A., Tervahartiala, T., Sorsa, T., Böckelman, C., & Haglund, C. (2018). Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 40(9), 1010428318799266.CrossRef

44.

Wang, C.-S., Wu, T.-L., Tsao, K.-C., & Sun, C.-F. (2006). Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Annals of Clinical and Laboratory Science, 36(1), 23–30.PubMed

45.

Gouyer, V., Conti, M., Devos, P., Zerimech, F., Copin, M.-C., Créme, E., Wurtz, A., Porte, H., & Huet, G. (2005). Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer, 103(8), 1676–1684.PubMedCrossRef

46.

Visscher, D. W., Höyhtyä, M., Ottosen, S. K., Liang, C.-M., Sarkar, F. H., Crissman, J. D., & Fridman, R. (1994). Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. International Journal of Cancer, 59(3), 339–344.PubMedCrossRef

47.

Ylisirniö, S., Höyhtyä, M., & Turpeenniemi-Hujanen, T. (2000). Serum matrix metalloproteinases-2,-9 and tissue inhibitors of metalloproteinases-1,-2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Research, 20(2B), 1311–1316.PubMed

48.

Drzewiecka-Jędrzejczyk, M., Wlazeł, R., Terlecka, M., & Jabłoński, S. (2017). Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients. Journal of Thoracic Disease, 9(12), 5306–5313.PubMedPubMedCentralCrossRef

49.

Suemitsu, R., Yoshino, I., Tomiyasu, M., Fukuyama, S., Okamoto, T., & Maehara, Y. (2004). Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surgery Today, 34(11), 896–901.PubMedCrossRef

50.

Giannelli, G., Bergamini, C., Marinosci, F., Fransvea, E., Quaranta, M., Lupo, L., Schiraldi, O., & Antonaci, S. (2002). Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. International Journal of Cancer, 97(4), 425–431.PubMedCrossRef

51.

Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. K., Baylin, S. B., & Graff, J. R. (1999). Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Research, 59(4), 798–802.PubMed

52.

Cymbaluk-Płoska, A., Chudecka-Głaz, A., Pius-Sadowska, E., Machaliński, B., Menkiszak, J., & Sompolska-Rzechuła, A. (2018). Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer. Journal of Ovarian Research, 11(1), 1.PubMedPubMedCentralCrossRef

53.

Gu, X., Fu, M., Ding, Y., Ni, H., Zhang, W., Zhu, Y., Tang, X., Xiong, L., Li, J., Qiu, L., Xu, J., & Zhu, J. (2014). TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC. PLoS One, 9(8), e106161.PubMedPubMedCentralCrossRef

54.

Sounni, N. E., Rozanov, D. V., Remacle, A. G., Golubkov, V. S., Noel, A., & Strongin, A. Y. (2010). Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells. International Journal of Cancer, 126(5), 1067–1078.PubMedPubMedCentral

55.

Valacca, C., Tassone, E., & Mignatti, P. (2015). TIMP-2 interaction with MT1-MMP activates the AKT pathway and protects tumor cells from apoptosis. PLoS One, 10(9), e0136797.PubMedPubMedCentralCrossRef

56.

Valente, P., Fassina, G., Melchiori, A., Masiello, L., Cilli, M., Vacca, A., Onisto, M., Santi, L., Stetler-Stevenson, W. G., & Albini, A. (1998). TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. International Journal of Cancer, 75(2), 246–253.PubMedCrossRef

57.

Forte, D., Salvestrini, V., Corradi, G., Rossi, L., Catani, L., Lemoli, R. M., Cavo, M., & Curti, A. (2017). The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. Oncotarget, 8(2), 2261.PubMedCrossRef

58.

Jiang, Y., Wang, M., Celiker, M. Y., Liu, Y. E., Sang, Q. X., Goldberg, I. D., & Shi, Y. E. (2001). Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Research, 61(6), 2365–2370.PubMed

59.

Scilabra, S. D., Troeberg, L., Yamamoto, K., Emonard, H., Thøgersen, I., Enghild, J. J., Strickland, D. K., & Nagase, H. (2013). Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1. The Journal of Biological Chemistry, 288(1), 332–342.PubMedCrossRef

60.

Emonard, H., Bellon, G., Troeberg, L., Berton, A., Robinet, A., Henriet, P., Marbaix, E., Kirkegaard, K., Patthy, L., Eeckhout, Y., Nagase, H., Hornebeck, W., & Courtoy, P. J. (2004). Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2. TIMP-2 complex through a thrombospondin-independent mechanism. The Journal of Biological Chemistry, 279(52), 54944–54951.PubMedCrossRef

61.

Hahn-Dantona, E., Ruiz, J. F., Bornstein, P., & Strickland, D. K. (2001). The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. The Journal of Biological Chemistry, 276(18), 15498–15503.PubMedCrossRef

62.

Jackson, H. W., Defamie, V., Waterhouse, P., & Khokha, R. (2017). TIMPs: versatile extracellular regulators in cancer. Nature Reviews Cancer, 17(1), 38–53.PubMedCrossRef

63.

Murphy, G. (2011). Tissue inhibitors of metalloproteinases. Genome Biology, 12(11), 233.PubMedPubMedCentralCrossRef

64.

Brew, K., & Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta, 1803(1), 55–71.PubMedPubMedCentralCrossRef

65.

Lambert, E., Bridoux, L., Devy, J., Dassé, E., Sowa, M.-L., Duca, L., Hornebeck, W., Martiny, L., & Petitfrère-Charpentier, E. (2009). TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival. The International Journal of Biochemistry & Cell Biology, 41(5), 1102–1115.CrossRef

66.

Tsagaraki, I., Tsilibary, E. C., & Tzinia, A. K. (2010). TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis. Cell and Tissue Research, 342(1), 87–96.PubMedCrossRef

67.

Zhang, J., Wu, T., Zhan, S., Qiao, N., Zhang, X., Zhu, Y., Yang, N., Sun, Y., Zhang, X. A., Bleich, D., & Han, X. (2017). TIMP-1 and CD82, a promising combined evaluation marker for PDAC. Oncotarget, 8(4), 6496–6512.PubMed

68.

Jung, K.-K., Liu, X.-W., Chirco, R., Fridman, R., & Kim, H.-R. C. (2006). Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. The EMBO Journal, 25(17), 3934–3942.PubMedPubMedCentralCrossRef

69.

Pols, M. S., & Klumperman, J. (2009). Trafficking and function of the tetraspanin CD63. Experimental Cell Research, 315(9), 1584–1592.PubMedCrossRef

70.

Groft, L. L., Muzik, H., Rewcastle, N. B., Johnston, R. N., Knäuper, V., Lafleur, M. A., Forsyth, P. A., & Edwards, D. R. (2001). Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. British Journal of Cancer, 85(1), 55–63.PubMedPubMedCentralCrossRef

71.

Rorive, S., Lopez, X. M., Maris, C., Trepant, A.-L., Sauvage, S., Sadeghi, N., Roland, I., Decaestecker, C., & Salmon, I. (2010). TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Modern Pathology, 23(10), 1418–1428.PubMedCrossRef

72.

Ahonen, M., Baker, A. H., & Kähäri, V.-M. (1998). Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Research, 58(11), 2310–2315.PubMed

73.

Zhang, H., Wang, Y.-S., Han, G., & Shi, Y. (2007). TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary & Pancreatic Diseases International: HBPD INT, 6(5), 487–491.CrossRef

74.

Amour, A., Knight, C. G., Webster, A., Slocombe, P. M., Stephens, P. E., Knäuper, V., Docherty, A. J. P., & Murphy, G. (2000). The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Letters, 473(3), 275–279.PubMedCrossRef

75.

Kashiwagi, M., Tortorella, M., Nagase, H., & Brew, K. (2001). TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). The Journal of Biological Chemistry, 276(16), 12501–12504.PubMedCrossRef

76.

Wang, W.-M., Ge, G., Lim, N. H., Nagase, H., & Greenspan, D. S. (2006). TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. The Biochemical Journal, 398(3), 515–519.PubMedPubMedCentralCrossRef

77.

Qi, J. H., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., & Anand-Apte, B. (2003). A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Medicine, 9(4), 407–415.PubMedCrossRef

78.

Kang, K.-H., Park, S.-Y., Rho, S. B., & Lee, J.-H. (2008). Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovascular Research, 79(1), 150–160.PubMedCrossRef

79.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMedCrossRef

80.

Klenotic, P. A., Munier, F. L., Marmorstein, L. Y., & Anand-Apte, B. (2004). Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. The Journal of Biological Chemistry, 279(29), 30469–30473.PubMedCrossRef

81.

Yu, W.-H., Shuan-su, C. Y., Meng, Q., Brew, K., & Woessner, J. F. (2000). TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. The Journal of Biological Chemistry, 275(40), 31226–31232.PubMedCrossRef

82.

Hayakawa, T., Yamashita, K., Ohuchi, E., & Shinagawa, A. (1994). Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). Journal of Cell Science, 107(Pt 9), 2373–2379.PubMed

83.

Hoegy, S. E., Oh, H.-R., Corcoran, M. L., & Stetler-Stevenson, W. G. (2001). Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. The Journal of Biological Chemistry, 276(5), 3203–3214.PubMedCrossRef

84.

Oh, J., Diaz, T., Wei, B., Chang, H., Noda, M., & Stetler-Stevenson, W. G. (2006). TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene, 25(30), 4230–4234.PubMedPubMedCentralCrossRef

85.

Seo, D.-W., Li, H., Qu, C.-K., Oh, J., Kim, Y.-S., Diaz, T., Wei, B., Han, J.-W., & Stetler-Stevenson, W. G. (2006). Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. The Journal of Biological Chemistry, 281(6), 3711–3721.PubMedCrossRef

86.

Fernandez, C. A., Roy, R., Lee, S., Yang, J., Panigrahy, D., van Vliet, K. J., & Moses, M. A. (2010). The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. The Journal of Biological Chemistry, 285(53), 41886–41895.PubMedPubMedCentralCrossRef

87.

D’Alessio, S., Ferrari, G., Cinnante, K., Scheerer, W., Galloway, A. C., Roses, D. F., Rozanov, D. V., Remacle, A. G., Oh, E.-S., & Shiryaev, S. A. (2008). Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism. The Journal of Biological Chemistry, 283(1), 87–99.PubMedCrossRef

88.

López-Otín, C., & Overall, C. M. (2002). Protease degradomics: a new challenge for proteomics. Nature Reviews Molecular Cell Biology, 3(7), 509–519.PubMedCrossRef

89.

Gomez, D. E., Alonso, D. F., Yoshiji, H., & Thorgeirsson, U. P. (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. European Journal of Cell Biology, 74(2), 111–122.PubMed

90.

Bode, W., & Maskos, K. (2003). Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biological Chemistry, 384(6), 863–872.PubMedCrossRef

91.

Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69(3), 562–573.PubMedCrossRef

92.

Maskos, K., & Bode, W. (2003). Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Molecular Biotechnology, 25(3), 241–266.PubMedCrossRef

93.

Tuuttila, A., Morgunova, E., Bergmann, U., Lindqvist, Y., Maskos, K., Fernandez-Catalan, C., Bode, W., Tryggvason, K., & Schneider, G. (1998). Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 Å resolution. Journal of Molecular Biology, 284(4), 1133–1140.PubMedCrossRef

94.

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera—a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612.PubMedCrossRef

95.

Gomis-R, F.-X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., & Bourenkov, G. P. (1997). Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature, 389(6646), 77–81.CrossRef

96.

Kumar, S., Stecher, G., & Tamura, K. (2016). MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Molecular Biology and Evolution, 33(7), 1870–1874.PubMedCrossRefPubMedCentral

97.

Wisniewska, M., Goettig, P., Maskos, K., Belouski, E., Winters, D., Hecht, R., Black, R., & Bode, W. (2008). Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. Journal of Molecular Biology, 381(5), 1307–1319.PubMedCrossRef

98.

Meng, Q., Malinovskii, V., Huang, W., Hu, Y., Chung, L., Nagase, H., Bode, W., Maskos, K., & Brew, K. (1999). Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate. The Journal of Biological Chemistry, 274(15), 10184–10189.PubMedCrossRef

99.

Wei, S., Chen, Y., Chung, L., Nagase, H., & Brew, K. (2003). Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors. The Journal of Biological Chemistry, 278(11), 9831–9834.PubMedCrossRef

100.

Lee, M.-H., Rapti, M., Knäuper, V., & Murphy, G. (2004). Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. The Journal of Biological Chemistry, 279(17), 17562–17569.PubMedCrossRef

101.

Rapti, M., Knäuper, V., Murphy, G., & Williamson, R. A. (2006). Characterization of the AB loop region of TIMP-2 involvement in pro-MMP-2 activation. The Journal of Biological Chemistry, 281(33), 23386–23394.PubMedCrossRef

102.

Fernandez-Catalan, C., Bode, W., Huber, R., Turk, D., Calvete, J. J., Lichte, A., Tschesche, H., & Maskos, K. (1998). Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. The EMBO Journal, 17(17), 5238–5248.PubMedPubMedCentralCrossRef

103.

Nagase, H., & Brew, K. (2003). Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochemical Society Symposium, 70, 201–212.

104.

Batra, J., Soares, A. S., Mehner, C., & Radisky, E. S. (2013). Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One, 8(9), e75836.PubMedPubMedCentralCrossRef

105.

Lee, M.-H., Rapti, M., & Murphy, G. (2005). Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. The Journal of Biological Chemistry, 280(16), 15967–15975.PubMedCrossRef

106.

Nagase, H., & Murphy, G. (2008). Tailoring TIMPs for selective metalloproteinase inhibition. In D. Edwards, G. Hoyer-Hansen, F. Blasi, & B. F. Sloane (Eds.), The Cancer Degradome (pp. 787–810). Springer.

107.

Rapti, M., Atkinson, S. J., Lee, M.-H., Trim, A., Moss, M., & Murphy, G. (2008). The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. The Biochemical Journal, 411(2), 433–439.PubMedCrossRef

108.

Morgunova, E., Tuuttila, A., Bergmann, U., & Tryggvason, K. (2002). Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7414–7419.PubMedPubMedCentralCrossRef

109.

Kobuch, J., Cui, H., Grünwald, B., Saftig, P., Knolle, P. A., & Krüger, A. (2015). TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice. Haematologica, 100(8), 1005–1013.PubMedPubMedCentral

110.

Cui, H., Grosso, S., Schelter, F., Mari, B., & Krüger, A. (2012). On the pro-metastatic stress response to cancer therapies: evidence for a positive co-operation between TIMP-1, HIF-1α, and miR-210. Frontiers in Pharmacology, 3, 134.PubMedPubMedCentralCrossRef

111.

Warner, R. B. (2013). Analysis of the structure and function of a TIMP-1/CD63 complex and its relationship to an MT1-MMP/CD63 complex. Wayne State University Dissertations. Paper 864, http://digitalcommons.wayne.edu/oa_dissertations. Accessed 10 Sep 2019.

112.

Mittal, S., & Saluja, D. (2015). Protein post-translational modifications: role in protein structure, function and stability. In Proteostasis and Chaperone Surveillance (pp. 25–37). Springer.

113.

Xin, F., & Radivojac, P. (2012). Post-translational modifications induce significant yet not extreme changes to protein structure. Bioinformatics (Oxford, England), 28(22), 2905–2913.CrossRef

114.

Darling, A. L., & Uversky, V. N. (2018). Intrinsic disorder and posttranslational modifications: the darker side of the biological dark matter. Frontiers in Genetics, 9, 158. https://doi.org/10.3389/fgene.2018.00158.

115.

Khoury, G. A., Baliban, R. C., & Floudas, C. A. (2011). Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Scientific Reports, 1, 90.PubMedCentralCrossRef

116.

Hart, G. W. (1992). Glycosylation. Current Opinion in Cell Biology, 4(6), 1017–1023.PubMedCrossRef

117.

Okada, Y., Watanabe, S., Nakanishi, I., Kishi, J.-I., Hayakawa, T., Watorek, W., Travis, J., & Nagase, H. (1988). Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Letters, 229(1), 157–160.PubMedCrossRef

118.

Nagase, H., Suzuki, K., Cawston, T. E., & Brew, K. (1997). Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1). The Biochemical Journal, 325(1), 163–167.PubMedPubMedCentralCrossRef

119.

Jackson, P. L., Xu, X., Wilson, L., Weathington, N. M., Clancy, J. P., Blalock, J. E., & Gaggar, A. (2010). Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Molecular Medicine (Cambridge, Mass.), 16(5-6), 159–166.

120.

Itoh, Y., & Nagase, H. (1995). Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. The Journal of Biological Chemistry, 270(28), 16518–16521.PubMedCrossRef

Titel: Functional disparities within the TIMP family in cancer: hints from molecular divergence
verfasst von: Celina Eckfeld
Daniel Häußler
Benjamin Schoeps
Chris D. Hermann
Achim Krüger
Publikationsdatum: 16.09.2019
Verlag: Springer US
Schlagwort: Metastasis
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09812-6

Springer Medizin

Functional disparities within the TIMP family in cancer: hints from molecular divergence

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer

KISS1 in breast Cancer progression and autophagy

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

The role of proteases in epithelial-to-mesenchymal cell transitions in cancer

Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors

Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie